ArticleEuropean journal of clinical pharmacology2026
Acute coronary syndrome as a turning point for guideline adherence and outcomes in heart failure with coronary artery disease and diabetes mellitus.
Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) patients with concomitant coronary artery disease (CAD) and type 2 diabetes mellitus (DM) represent a particularly high-risk population with increased morbidity and mortality. Acute coronary syndrome (ACS) often serves as a critical event that can trigger optimization of guideline-directed medical therapy (GDMT). However, the impact of ACS on long-term adherence patterns and outcomes in this population remains unclear.
methodsWe retrospectively studied 431 patients with HF (LVEF ≤ 40%), CAD, and DM presenting with ACS between 2019 and 2022. Adherence to nine evidence-based therapies was scored (0-9) and classified as poor (0-3), intermediate (4-6), or good (7-9). Adherence was assessed before ACS and over 36 months of follow-up. Primary outcomes were rehospitalization and all-cause mortality, analyzed using Cox regression and Kaplan-Meier methods.
resultsMean age was 62.1 ± 10.2 years, and 64.7% were male. Before ACS, 45.9% had poor adherence and only 16.0% had good adherence. After ACS, poor adherence dropped to 7.9%, while good adherence rose to 62.2% (p < 0.001). Statin use increased from 22.3% to 82.4%, ACEi/ARB/ARNI from 58.2% to 89.3%, beta-blockers from 44.8% to 86.8%, and MRAs from 23.4% to 67.3%. Gender-specific analyses showed parallel gains: poor adherence declined from 44.8% to 6.5% in men and from 40.1% to 5.3% in women, with good adherence exceeding 67% in both groups. Patients with good adherence had significantly lower risks of rehospitalization (HR 0.52) and mortality (HR 0.46). Independent adverse outcome predictors were low hemoglobin, high HbA1c, impaired renal function, and reduced LVEF.
conclusionACS serves as a catalyst for improved GDMT adherence in HF patients with CAD and DM. Higher adherence is strongly associated with reduced rehospitalization and mortality, underscoring the need for sustained adherence strategies and multidisciplinary care models to optimize long-term outcomes.
Indexed as
Identifiers
41553512What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.